We’re glad to see you’re enjoying ReachMD…but how about a more personalized experience?
Why Do We Need New Therapies for Sickle Cell Disease?
Biree Andemariam, MD
Caroline Freiermuth, MD
Let’s Discuss Transplantation
Cell and Gene Therapies for Sickle Cell Disease
Implementing the Sickle Cell Treatment Regimen
Preventative Management of Sickle Cell Disease Complications
Making the Transition: Managing Patients with Sickle Cell Disease Across the Lifespan
Improving Communication Across Care Settings
Understanding the Fine Print: The Who, When, And What To Do About ARIA in Patients with Alzheimer’s Disease - Emergency Medicine Module
James Galvin, MD, MPH, FANA
Gloria Chiang, MD
Christopher Carpenter, MD, MSC, FACEP, FAAEM, AGSF
Understanding the Fine Print: The Who, When, And What To Do About ARIA in Patients with Alzheimer’s Disease - Closing Module
Charles P. Vega, MD
Real World Data and the Management of Intracranial Hemorrhages (ICH) in Anticoagulated Patients
W. Brian Gibler, MD, FACEP, FACC, FAHA
Natalie Kreitzer, MD, MS
Adrian R. Parry-Jones, FRCP, PhD
David Seiffge, MD
Repletion or Reversal? Optimizing Specific Therapy for Direct Oral Anticoagulant (DOAC)-Related Life-Threatening Bleeding Using Real-World Experience
Case Presentation: Management of a Patient With Vitamin K Antagonist-Associated Intracranial Hemorrhage (ICH)
Repletion Management for Vitamin K Antagonist Anticoagulation
Reversal of Factor Xa Inhibitor ICH: ANNEXA-4, ANNEXA-I and Real-World Evidence
Case Presentation: Management of a Patient With Factor Xa-Associated ICH Using Specific Reversal Therapy
Press cancel to remain on ReachMD. Press the link below or the continue button to keep going.
Stay current with the best on medical education